Randomized Carbon Ions vs Standard Radiotherapy for Radioresistant Tumors

Inclusion Criteria: * age ≥ 18 years * No severe comorbidity, life expectancy above 10 years * Unresectable or inoperable or R2 resection of the tumor * Eligible radioresistant tumor according to the limitative list as following: * adenoid cystic carcinoma of head and neck (larynx and trachea excluded) * soft tissue sarcoma * pleomorphic rhabdomyosarcoma only (alveolar and embryonal forms excluded) * retroperitoneal sarcoma under condition of technical feasibility (movement) * osteosarcoma of any grade and localisation (Ewing excluded) * chondrosarcoma (except of skull base) OMS grade \>= 2 * chordoma axial skeleton or pelvis (except of skull base) * angiosarcoma * Absence of epidermal invasion (a hypodermic invasion is accepted with fixity of cutaneous plan but not true epidermal permeation) * Larger volume to be irradiated (PTV) less than 25 cm * ECOG Performance Status ≤ 2 or Karnovsky index ≥ 60 * no pregnancy of possibility of pregnancy during the treatment * having an health insurance * signature of a written informed consent * validation of the randomization criteria: namely, a carbon ions therapy indication assessed by the medical team of a hadrontherapy center and able to by treated within two month from registration. Exclusion Criteria: * Complete macroscopic or microscopic surgical resection (R0 or R1) * previous irradiation in the volume to be treated * metastatic disease * disease not candidate to a curative approach (example accelerated progressive diseaseresistant to nay medical treatment especially for sarcoma) * any contra-indication to undergo a radiation therapy by Xray or particle therapy * planned surgery or chemotherapy to take place after completion of radiotherapy (example : absence of enough space between an organ risk and the target volume (at least 5 mm) except the possibility of a spacer insertion) * planned surgery or chemotherapy after radiotherapy * Presence in the target volume of metallic material which cannot be removed (carbon fibres matreial authorized) * history of concomittant (except in situ cervix carcinoma; or any cured basocellular cutaneous cancer tor any cured cancer with no sign of relapse during 5 years)) * impossible follow-up over 5 years